Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-alpha and Antineoplastic Drugs.

Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-alpha and Antineoplastic Drugs. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-alpha and Antineoplastic Drugs. Abstract Text:

M J Czejka,J Schueller,H Kletzl,S Strauch,C Pietrzak,

The major problems in chemotherapy are occasional low response rates in patients despite favourable in vitro action, the development of drug resistance and long or short term adverse effects. Therefore, in the past decade efforts have been made to circumvent these problems by combining antineoplastic drugs with biomodulating or cytoprotective agents. Most of the clinically useful drug regimens consist of a cocktail of drugs with different mechanisms of action, and hence different toxicity profiles. Dose-limiting factors in regard to toxicity and therapeutic efficacy predominate, and it is therefore clinically essential to know whether or not a pharmacokinetic drug interaction occurs. The introduction of interferon-alpha (IFNalpha) in chemotherapy is an alternative investigational approach to amplify the cytotoxicity of an antineoplastic drug in order to increase tumour response. Most of the clinical studies reported with IFNalpha provide useful information and identify major pharmacodynamic interactions, but only a few focus on and report potential pharmacokinetic interactions between antineoplastic drugs and IFNalpha in patients. The broad spectrum of antineoplastic drugs whose activity can be enhanced by IFNalpha argues for multiple levels of drug-drug interactions: protein binding (cisplatin), alteration in cellular uptake, modulation of drug target enzymes (dihydropyrimidine hydrogenase) and changes in biotransformation (tretinoin) or excretion. Pharmacokinetic and/or pharmacodynamic interactions may be beneficial (fluorouracil) or sometimes detrimental and coincidental (doxorubicin). This article focuses on observed pharmacokinetic drug interactions between IFNalpha and antineoplastic drugs and discusses possible mechanisms of action.

Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-alpha and Antineoplastic Drugs. Publishing Authors By Initials

MJ Czejka,J Schueller,H Kletzl,S Strauch,C Pietrzak,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-alpha and Antineoplastic Drugs. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: BioDrugs : clinical immunotherapeutics, biopharmac

VOLUME: 11

Page Numbers: 87-101

Journal Abbreviation:

ISSN: 1173-8804

DAY: 22

MONTH: Feb

YEAR: 1999

Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-alpha and Antineoplastic Drugs. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9705305

Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-alpha and Antineoplastic Drugs. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-alpha and Antineoplastic Drugs. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-alpha and Antineoplastic Drugs.

AFFILIATION: Institute of Pharmaceutical Chemistry, Pharmacokinetic Department, University of Vienna, Vienna, Austria.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: BioDrugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-alpha and Antineoplastic Drugs Related Publications

• Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-alpha and Antineoplastic Drugs.
• Collagenoses and cutaneous manifestations of hepar diseases.
• Dega's transiliac osteotomy in the treatment of spastic hip subluxation and dislocation in cerebral palsy.
• Double osteotomy in the surgical treatment of Perthes' disease: Dega's transiliac osteotomy and subtrochanteric osteotomy.
• Etanercept in psoriasis treatment.
• Indications for psychological intervention in patients with psoriasis.
• Neurodevelopmental rehabilitation according to Glenn Doman (the Philadelphia Neurodevelopment Method).
• Plasma activity of interleukin-10 in drug-induced cutaneous reactions.
• Rapid cooling through the glass transition transiently increases ductility of PGA/PLLA copolymers: a proposed mechanism and implications for devices.
• [A new sign for the establishment of gunshot in suicide?]
• [Closure of spontaneous nasal septum defect with fascia]
• [Evaluation of outcomes following total hip arthroplasty]
• [Immunoglobulins and circulating immunologic complexes in serum of patients with psoriasis, lichen planus and pityriasis rosea]